Vineet Laboratories Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 2/6

Vineet Laboratories hat ein Gesamteigenkapital von ₹307.7M und eine Gesamtverschuldung von ₹405.7M, wodurch sich der Verschuldungsgrad auf 131.9% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen ₹1.1B bzw. ₹757.7M. Vineet Laboratories Das EBIT des Unternehmens beträgt ₹543.9K, so dass der Zinsdeckungsgrad 0 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von ₹3.1M.

Wichtige Informationen

131.9%

Verhältnis von Schulden zu Eigenkapital

₹405.73m

Verschuldung

Zinsdeckungsgrad	0.01x
Bargeld	₹3.13m
Eigenkapital	₹307.65m
Gesamtverbindlichkeiten	₹757.66m
Gesamtvermögen	₹1.07b

Jüngste Berichte zur Finanzlage

Vineet Laboratories (NSE:VINEETLAB) Seems To Be Using A Lot Of Debt

Jul 12

We Think Vineet Laboratories (NSE:VINEETLAB) Is Taking Some Risk With Its Debt

Feb 15

Recent updates

Vineet Laboratories (NSE:VINEETLAB) Seems To Be Using A Lot Of Debt

Jul 12

Earnings Working Against Vineet Laboratories Limited's (NSE:VINEETLAB) Share Price Following 25% Dive

Mar 07

We Think Vineet Laboratories (NSE:VINEETLAB) Is Taking Some Risk With Its Debt

Feb 15

With EPS Growth And More, Vineet Laboratories (NSE:VINEETLAB) Makes An Interesting Case

Nov 14

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: VINEETLABDie kurzfristigen Aktiva des Unternehmens (₹783.8M) übersteigen seine kurzfristigen Passiva (₹681.8M).

Langfristige Verbindlichkeiten: VINEETLABDie kurzfristigen Vermögenswerte des Unternehmens (₹783.8M) übersteigen seine langfristigen Verbindlichkeiten (₹75.9M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: VINEETLABDie Nettoverschuldung im Verhältnis zum Eigenkapital (130.9%) wird als hoch angesehen.

Schulden abbauen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob das Verhältnis von Schulden zu Eigenkapital in den letzten 5 Jahren gesunken ist ( VINEETLAB).

Schuldendeckung: VINEETLABDie Schulden des Unternehmens sind nicht ausreichend durch den operativen Cashflow (1.7%) gedeckt.

Zinsdeckung: VINEETLABDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (0x Deckung) nicht gut gedeckt.

Vineet Laboratories Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Vineet Laboratories (NSE:VINEETLAB) Seems To Be Using A Lot Of Debt

We Think Vineet Laboratories (NSE:VINEETLAB) Is Taking Some Risk With Its Debt

Recent updates

Less than half of directors are independent

Second quarter 2025 earnings released: ₹1.98 loss per share (vs ₹2.62 profit in 2Q 2024)

Vineet Laboratories Limited Announces Resignation of Bhaskara Reddy Karna as Independent Director

Vineet Laboratories Limited to Report Q2, 2025 Results on Nov 13, 2024

Vineet Laboratories Limited, Annual General Meeting, Sep 27, 2024

First quarter 2025 earnings released: ₹2.31 loss per share (vs ₹1.36 loss in 1Q 2024)

Vineet Laboratories Limited to Report Q1, 2025 Results on Aug 13, 2024

Investor sentiment improves as stock rises 20%

Vineet Laboratories (NSE:VINEETLAB) Seems To Be Using A Lot Of Debt

Full year 2024 earnings released: EPS: ₹1.11 (vs ₹1.36 in FY 2023)

Vineet Laboratories Limited Announces Resignation of Satish Pandurang Samant as Executive Director

New minor risk - Share price stability

Vineet Laboratories Limited to Report Q4, 2024 Results on May 29, 2024

Investor sentiment improves as stock rises 19%

Earnings Working Against Vineet Laboratories Limited's (NSE:VINEETLAB) Share Price Following 25% Dive

We Think Vineet Laboratories (NSE:VINEETLAB) Is Taking Some Risk With Its Debt

Third quarter 2024 earnings released: ₹2.22 loss per share (vs ₹1.51 profit in 3Q 2023)

Vineet Laboratories Limited to Report Q3, 2024 Results on Feb 12, 2024

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 32%

With EPS Growth And More, Vineet Laboratories (NSE:VINEETLAB) Makes An Interesting Case

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: ₹2.62 (vs ₹5.10 loss in 2Q 2023)

Vineet Laboratories Limited Announces Appointment of Mr. Rameshkumar Bandari as Company Secretary and Compliance Officer

Vineet Laboratories Limited to Report Q2, 2024 Results on Nov 10, 2023

Vineet Laboratories Limited Announces Resignation of Nirosha Ravikanti as Company Secretary / Compliance Officer of the Company

Vineet Laboratories Limited Appoints Mr. Satish Pandurang Samant as Chief Executive Officer

Vineet Laboratories Limited Appoints Mr. Satish Pandurang Samant as Chief Executive Officer

Vineet Laboratories Limited, Annual General Meeting, Sep 28, 2023

Vineet Laboratories Limited Announces Board Changes

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: ₹1.36 loss per share (vs ₹1.10 profit in 1Q 2023)

Investor sentiment improves as stock rises 22%

Vineet Laboratories Limited to Report Q1, 2024 Results on Aug 12, 2023

Full year 2023 earnings released: EPS: ₹1.36 (vs ₹7.20 in FY 2022)

Vineet Laboratories Limited to Report Q4, 2023 Results on May 29, 2023

Investor sentiment improves as stock rises 23%

MD & Director recently bought ₹333k worth of stock

MD & Director recently bought ₹416k worth of stock

MD & Director recently bought ₹868k worth of stock

MD & Director recently bought ₹430k worth of stock

Investor sentiment deteriorates as stock falls 16%

Third quarter 2023 earnings released: EPS: ₹1.51 (vs ₹3.52 in 3Q 2022)

Vineet Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

Investor sentiment improved over the past week

Second quarter 2023 earnings released: ₹5.10 loss per share (vs ₹3.52 profit in 2Q 2022)

High number of new and inexperienced directors

Vineet Laboratories Limited Approves Change the Designation of Kandula Murali Mohan from Non- Executive Director to Whole Time Director

Vineet Laboratories Limited, Annual General Meeting, Sep 28, 2022

First quarter 2023 earnings released: EPS: ₹1.10 (vs ₹2.18 in 1Q 2022)

Vineet Laboratories Limited Appoints Mrs. Yerukalapudi Hari Priya as Additional Independent Director (Non-Executive)

Vineet Laboratories Limited to Report Q1, 2023 Results on Jul 29, 2022

Vineet Laboratories Limited Announces Resignation of Thotakura Uma Sangeetha as Independent Director

Investor sentiment improved over the past week

Vineet Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

Vineet Laboratories Limited to Report Q4, 2022 Results on May 28, 2022

Investor sentiment improved over the past week

High number of new and inexperienced directors

Investor sentiment improved over the past week

High number of new and inexperienced directors

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen